Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues

International Journal of Cancer

Volumn 132, Issue 6, 2013, Pages 1368-1382

  Takadate, Tatsuyuki ^a   Onogawa, Tohru ^a   Fukuda, Tetsuya ^b   Motoi, Fuyuhiko ^a   Suzuki, Takashi ^a   Fujii, Kiyonaga ^c   Kihara, Makoto ^d   Mikami, Sayaka ^b   Bando, Yasuhiko ^b   Maeda, Shimpei ^a   Ishida, Kazuyuki ^a   Minowa, Takashi ^e   Hanagata, Nobutaka ^e   Ohtsuka, Hideo ^a   Katayose, Yu ^a   Egawa, Shinichi ^a   Nishimura, Toshihide ^f   Unno, Michiaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Biosys Technologies Inc   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d Medical ProteoScope Company Ltd   (Japan)

^e NATIONAL INSTITUTE FOR MATERIALS SCIENCE   (Japan)

^f TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

formalin fixed paraffin embedded (FFPE); laser microdissection (LMD); liquid chromatography tandem mass spectrometry (LC MS MS); pancreatic cancer; scheduled selected reaction monitoring (sSRM)

Indexed keywords

BIOLOGICAL MARKER; FORMALDEHYDE; PROGNOSTIC PROTEIN; PROTEIN ECH1; PROTEIN GTR1; PROTEIN OLFM4; PROTEIN STML2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; EMBEDDING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MONITORING; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SHOTGUN PROTEOMICS; TANDEM MASS SPECTROMETRY; TREATMENT DURATION;

AGED; CARCINOMA, PANCREATIC DUCTAL; CHROMATOGRAPHY, LIQUID; FEMALE; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PARAFFIN EMBEDDING; PROGNOSIS; PROTEOMICS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84872952806     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27797     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA. Cancer J Clin 2009; 59: 225-49.
2. Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas 2004; 28: 219-30. (Pubitemid 38437313)
3. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors. J Am Coll Surg 2004; 198: 722-31. (Pubitemid 38542900)
4. Kim R, Tsao R, Tan A, et al. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators. J Gastrointest Surg 2010; 14: 1159-69.
5. Lim JE, Chien MW, Earle CC,. Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg 2003; 237: 74-85. (Pubitemid 36622320)
6. Motoi F, Rikiyama T, Katayose Y, et al. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines. Ann Surg Oncol 2011; 18: 371-9.
7. Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008; 247: 456-62.
8. Wulfkuhle JD, Liotta LA, Petricoin EF,. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003; 3: 267-75. (Pubitemid 37328862)
9. Grantzdorffer I, Carl-McGrath S, Ebert MP, et al. Proteomics of pancreatic cancer. Pancreas 2008; 36: 329-36. (Pubitemid 351591573)
10. Rocken C, Ebert MP, Roessner A,. Proteomics in pathology, research and practice. Pathol Res Pract 2004; 200: 69-82. (Pubitemid 38950437)
11. Aebersold R, Mann M,. Mass spectrometry-based proteomics. Nature 2003; 422: 198-207. (Pubitemid 36362757)
12. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-7. (Pubitemid 34178440)
13. Wolters DA, Washburn MP, Yates JR, III,. An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 2001; 73: 5683-90. (Pubitemid 33126725)
14. Picotti P, Bodenmiller B, Mueller LN, et al. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009; 138: 795-806.
15. Anderson NL, Anderson NG,. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845-67.
16. Prieto DA, Hood BL, Darfler MM, et al. Liquid Tissue: proteomic profiling of formalin-fixed tissues. Biotechniques 2005; 38 (S6): S32-5.
17. Kawamura T, Nomura M, Tojo H, et al. Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma. J Proteomics 2010; 73: 1089-99.
18. Nishimura T, Nomura M, Tojo H, et al. Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. J Proteomics 2010; 73: 1100-10.
19. Chen R, Pan S, Aebersold R, et al. Proteomics studies of pancreatic cancer. Proteomics Clin Appl 2007; 1: 1582-91.
20. Kawase H, Fujii K, Miyamoto M, et al. Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues. J Proteome Res 2009; 8: 4092-103.
21. Old WM, Meyer-Arendt K, Aveline-Wolf L, et al. Comparison of label-free methods for quantifying human proteins by shotgun proteomics. Mol Cell Proteomics 2005; 4: 1487-502. (Pubitemid 41555475)
22. Paoletti AC, Parmely TJ, Tomomori-Sato C, et al. Quantitative proteomic analysis of distinct mammalian Mediator complexes using normalized spectral abundance factors. Proc Natl Acad Sci USA 2006; 103: 18928-33. (Pubitemid 350002805)
23. Zhang B, VerBerkmoes NC, Langston MA, et al. Detecting differential and correlated protein expression in label-free shotgun proteomics. J Proteome Res 2006; 5: 2909-18. (Pubitemid 44749209)
24. Ferguson RE, Carroll HP, Harris A, et al. Housekeeping proteins: A preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics 2005; 5: 566-71. (Pubitemid 40262073)
25. Sung JY, Kim GY, Lim SJ, et al. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract 2010; 206: 24-9.
26. Cecconi D, Palmieri M, Donadelli M,. Proteomics in pancreatic cancer research. Proteomics 2011; 11: 816-28.
27. Hung KE, Yu KH,. Proteomic approaches to cancer biomarkers. Gastroenterology 2010; 138: 46-51 e1.
28. Ong SE, Mann M,. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005; 1: 252-62.
29. Tuli L, Ressom HW,. LC-MS Based Detection of Differential Protein Expression. J Proteomics Bioinform 2009; 2: 416-38.
30. Turtoi A, Mazzucchelli GD, de Pauw E,. Isotope coded protein label quantification of serum proteins - comparison with the label-free LC-MS and validation using the MRM approach. Talanta 2010; 80: 1487-95.
31. Ito H, Duxbury M, Zinner MJ, et al. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery 2004; 136: 548-56. (Pubitemid 39186566)
32. Zhang D, Liang X, He XY, et al. Delta 3,5,delta 2,4-dienoyl-CoA isomerase is a multifunctional isomerase. A structural and mechanistic study. J Biol Chem 2001; 276: 13622-7.
33. Nishigaki R, Osaki M, Hiratsuka M, et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics 2005; 5: 3205-13. (Pubitemid 41176488)
34. Song B, Tang JW, Wang B, et al. Identify lymphatic metastasis-Associated genes in mouse hepatocarcinoma cell lines using gene chip. World J Gastroenterol 2005; 11: 1463-72. (Pubitemid 40468081)
35. Yokoyama Y, Kuramitsu Y, Takashima M, et al. Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics 2004; 4: 2111-6. (Pubitemid 38880376)
36. Zhang J, Song M, Wang J, et al. Enoyl coenzyme A hydratase 1 is an important factor in the lymphatic metastasis of tumors. Biomed Pharmacother 2011; 65: 157-62.
37. Zhang X, Huang Q, Yang Z, et al. GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res 2004; 64: 2474-81. (Pubitemid 38523902)
38. Koshida S, Kobayashi D, Moriai R, et al. Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci 2007; 98: 315-20. (Pubitemid 46195600)
39. Kobayashi D, Koshida S, Moriai R, et al. Olfactomedin 4 promotes S-phase transition in proliferation of pancreatic cancer cells. Cancer Sci 2007; 98: 334-40. (Pubitemid 46195603)
40. Wang Y, Morrow JS,. Identification and characterization of human SLP-2, a novel homologue of stomatin (band 7.2b) present in erythrocytes and other tissues. J Biol Chem 2000; 275: 8062-71. (Pubitemid 30159719)
41. Zhang L, Ding F, Cao W, et al. Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res 2006; 12: 1639-46.
42. Chang D, Ma K, Gong M, et al. SLP-2 overexpression is associated with tumour distant metastasis and poor prognosis in pulmonary squamous cell carcinoma. Biomarkers 2010; 15: 104-10.
43. Pessin JE, Bell GI,. Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu Rev Physiol 1992; 54: 911-30.
44. Hatanaka M,. Transport of sugars in tumor cell membranes. Biochim Biophys Acta 1974; 355: 77-104.
45. Rudlowski C, Moser M, Becker AJ, et al. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 2004; 66: 404-10. (Pubitemid 39194363)
46. Sakashita M, Aoyama N, Minami R, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer 2001; 37: 204-9. (Pubitemid 32144697)